Home › Trials › NCT07052266
Clinical trial Recruiting at 4 sites Interventional Ages 18 to 55 Women only

Combined carrier and hereditary cancer screening offered during pregnancy or preconception

Official title: Feasibility of Obstetric and Cancer Universal Screening

Run by Weill Medical College of Cornell University · NCT07052266 · Data updated 2026-11-12

This project will test if pregnant and preconception patients will choose hereditary cancer genetic testing when it's offered alongside routine carrier screening.

More Hereditary Cancer Syndromes trials

Quick facts

Study typeInterventional
Ages18 Years to 55 Years
SexWomen only
Enrollment550 (estimated)
SponsorWeill Medical College of Cornell University
Academic / other
Locations5 sites (Brooklyn, New York and 4 other locations)
StatusRecruiting
StartedSeptember 2, 2025
Main results expectedJune 2027
Study endsDecember 2028
Registry record updatedDecember 26, 2025
Trial IDNCT07052266 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients aged 18–55 receiving prenatal or preconception/fertility care at WCM-affiliated sites who have elected obstetric carrier screening and can read English or Spanish, and who have not already completed a multigene hereditary cancer panel.

Probably not a fit

Patients who already completed a multigene hereditary cancer panel, who have a hematologic cancer or hematologic precancer, or who have had an autologous bone marrow transplant are excluded and unlikely to benefit from this screening offer.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial offers combined hereditary cancer screening using the MyRisk hereditary cancer test alongside standard obstetric carrier screening to patients receiving prenatal or preconception/fertility care at Weill Cornell Medicine–affiliated sites. Eligible participants aged 18–55 who elect carrier screening and who speak English or Spanish are invited to add hereditary cancer testing unless they have had a prior multigene hereditary cancer panel, hematologic cancer or precancer, or an autologous bone marrow transplant. The study will measure uptake, patient interest, acceptability, and demographic patterns of acceptance, and will explore implications for early prevention and cost-effectiveness. Data will be used to determine whether integrating hereditary cancer screening into obstetric workflows is feasible and could reduce under-recognition of inherited cancer risk.

Why it matters

Potential benefit: If successful, offering hereditary cancer screening in obstetric care could identify people with inherited cancer risk earlier and allow preventive steps that reduce cancer-related harm.

How similar studies have gone: This is a relatively novel integration—prior work shows carrier screening is commonly accepted but few programs have formally added hereditary cancer screening into routine obstetric care.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age 18 years - 55 years
* Pregnant patients receiving obstetrical-related care or receiving preconception/fertility care at a WCM-affiliated enrollment site.
* Patients who have elected to undergo OCS with the WCM-affiliated obstetrics provider
* Patients with prior OCS but planned to repeat OCS are eligible
* Patients can speak and read in English or Spanish

Exclusion Criteria:

* Patients who have previously completed a multigene hereditary cancer syndrome panel
* Patients who have a hematologic cancer or hematologic pre-cancer
* Patients who have a history of an autologous bone marrow transplant

Where it's running

  • Reproductive Medicine
    Brooklyn, New York, United States     Recruiting
  • Reproductive Medicine
    New York, New York, United States     Recruiting
  • Weill Cornell Medicine
    New York, New York, United States     Recruiting
  • NewYork-Presbyterian Weill Cornell Medicine Queens
    Queens, New York, United States     Recruiting
  • NewYork-Presbyterian Weill Cornell Medicine
    Brooklyn, New York, United States     Not yet recruiting

Study contacts

  • Principal investigator: Melissa Frey, MD, MS — Weill Medical College of Cornell University
  • Study coordinator: Steve Lopez, BA
  • Email: stl4013@med.cornell.edu
  • Phone: 9143127488

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Hereditary Cancer Syndromes 4Weill Medical College of Cornell University 137
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.